Gujarat Themis Biosyn Ltd has announced the successful completion of its fermentation block expansion at its manufacturing facility in Vapi, Gujarat. The company confirmed that the first batch of commercial production of Rifamycin-S and Rifamycin-O commenced on Saturday, October 18, 2025.
With this expansion, Gujarat Themis Biosyn’s total fermentation capacity has nearly doubled — rising from 450 KL to 990 KL. This marks a major milestone in the company’s growth strategy, enhancing its ability to manufacture multiple fermentation-based products.
The expansion positions Gujarat Themis Biosyn to capitalize on the increasing demand and growth opportunities in the fermentation segment, further strengthening its leadership in the pharmaceutical manufacturing space.